Evidence map›Paper›PMID 35406740›Full record

ArticleCells2022

A Heme-Binding Transcription Factor BACH1 Regulates Lactate Catabolism Suggesting a Combined Therapy for Triple-Negative Breast Cancer.

Joselyn Padilla, Bok-Soon Lee, Karen Zhai, Bethany Rentz, Tia Bobo, Norca Maritza Dowling, Jiyoung Lee

Open access · goldAbstract read
In one paragraph

Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Lactate and lactylation in intervertebral disc degeneration.Frontiers in molecular biosciences · 2025
    Review
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Joselyn PadillaDepartment of Biochemistry and Molecular Medicine, School of Medicine and Health Sciences, Washington, DC 20037, USA.
Bok-Soon LeeDepartment of Biochemistry and Molecular Medicine, School of Medicine and Health Sciences, Washington, DC 20037, USA.ORCID 0000-0002-0896-2883
Karen ZhaiDepartment of Biochemistry and Molecular Medicine, School of Medicine and Health Sciences, Washington, DC 20037, USA.
Bethany RentzAnimal Research, Office of the Vice Provost for Research, 1922 F Street NW, Washington, DC 20052, USA.
Tia BoboAnimal Research, Office of the Vice Provost for Research, 1922 F Street NW, Washington, DC 20052, USA.
Norca Maritza DowlingDepartment of Acute & Chronic Care, School of Nursing, Washington, DC 20037, USA.
Jiyoung LeeDepartment of Biochemistry and Molecular Medicine, School of Medicine and Health Sciences, Washington, DC 20037, USA.ORCID 0000-0001-8503-4805
George Washington University · USMilken Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The oncogenic expression or mutation of tumor suppressors drives metabolic alteration, causing cancer cells to utilize diverse nutrients. Lactate is a known substrate for cancer cells, yet the regulatory mechanisms of lactate catabolism are limited. Here, we show that a heme-binding transcription factor, BACH1, negatively regulates lactate catabolic pathways in triple-negative breast cancer (TNBC) cells. BACH1 suppresses the transcriptional expression of monocarboxylate transporter 1 (MCT1) and lactate dehydrogenase B, inhibiting lactate-mediated mitochondrial metabolism. In our studies, the depletion of BACH1 either genetically or pharmacologically increased the lactate use of TNBC cells, increasing their sensitivity to MCT1 inhibition. Thus, small inhibitory molecules (SR13800 and AZD3965) blocking MCT1 better suppressed the growth of BACH1-depleted TNBC cells than did the controls. Particularly, hemin treatment degrading BACH1 proteins induced lactate catabolism in TNBC cells, generating synthetic lethality with MCT1 inhibition. Our data indicates that targeting BACH1 generates metabolic vulnerability and increases sensitivity to lactate transporter inhibition, suggesting a potential novel combination therapy for cancer patients with TNBC.

Indexed as

Basic-Leucine Zipper Transcription FactorsLactic AcidTriple Negative Breast NeoplasmsHemeHumansMonocarboxylic Acid TransportersTranscription FactorsBACH1 protein, humanBasic-Leucine Zipper Transcription FactorsHemeLactic AcidMonocarboxylic Acid TransportersTranscription FactorsBACH1lactate catabolismlactate transporternovel combination therapy targeting BACH1 and MCT1triple-negative breast cancer

Identifiers

PMID35406740
PMCPMC8997507
OpenAlexW4221135881

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.